This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khalkhali-Ellis, Z. Articles by Hendrix, M. J. C. Search for Related Content PubMed PubMed Citation Articles by Khalkhali-Ellis, Z. Articles by Hendrix, M. J. C.

Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells

A Potential Mechanism for the Anticancer Properties of Tamoxifen

¹ Department of Anatomy and Cell Biology and the ² Holden Comprehensive Cancer Center at The University of Iowa, and Departments of ³ Pathology and ⁴ Biochemistry at The University of Iowa, The Roy J. and Lucile A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa

ABSTRACT

Purpose: Mammary epithelial cells and the majority of breast cancer tumors require estrogen for continued growth. Antiestrogen therapy alone, or in combination with other drugs, has long been a common procedure for breast cancer treatment and prophylaxis. Thus, there is a critical need to elucidate the mechanism(s) of action of antiestrogen treatment, especially for patients who are at risk of breast cancer development or who are currently receiving hormone therapy. In this study, we examined the ability of hormones to regulate the expression of a tumor suppressor gene, maspin, which is a serine protease inhibitor (serpin) that plays an important role in mammary gland development and is silenced during breast cancer progression. Specifically, our hypothesis tested the clinical efficacy of tamoxifen to regulate maspin expression.

Experimental Design: We used maspin promoter luciferase reporter plasmids that were transfected into normal human mammary epithelial (HMEC1331) and MCF-7 breast cancer cells, followed by determination of the effect of hormones and their antagonists on maspin promoter activity. At the protein level, cytosolic fractions from both cell types before and after hormone treatment were subjected to Western blot analysis to determine maspin level.

Results and Conclusions: Our studies revealed that the antiestrogen tamoxifen induces maspin promoter activity. Interestingly, antiandrogen flutamide could also induce maspin in both cell lines tested. These observations were further confirmed in patient tissues. These novel findings provide a new mechanism of action for tamoxifen under normal and pathological conditions. More significantly, these findings could have a potential impact on future therapeutic intervention strategies for breast cancer.

This article has been cited by other articles:

				Z. Khalkhali-Ellis Maspin: The New Frontier Clin. Cancer Res., December 15, 2006; 12(24): 7279 - 7283. [Abstract] [Full Text] [PDF]

				A. Dokras, J. Coffin, L. Field, A. Frakes, H. Lee, A. Madan, T. Nelson, G.-Y. Ryu, J.-G. Yoon, and A. Madan Epigenetic regulation of maspin expression in the human placenta Mol. Hum. Reprod., October 1, 2006; 12(10): 611 - 617. [Abstract] [Full Text] [PDF]

				S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF]

				C. M. Bailey, Z. Khalkhali-Ellis, S. Kondo, N. V. Margaryan, R. E. B. Seftor, W. W. Wheaton, S. Amir, M. R. Pins, B. C. Schutte, and M. J. C. Hendrix Mammary Serine Protease Inhibitor (Maspin) Binds Directly to Interferon Regulatory Factor 6: IDENTIFICATION OF A NOVEL SERPIN PARTNERSHIP J. Biol. Chem., October 7, 2005; 280(40): 34210 - 34217. [Abstract] [Full Text] [PDF]